SOX9 predicts progression towards cirrhosis in patients while its loss protects against liver fibrosis by Athwal, Varinder S. et al.
Athwal, Varinder S. and Pritchett, James and Llewellyn, 
Jessica and Martin, Katherine and Camacho, Elizabeth 
and Raza, Sayyid M.A. and Phythian-Adams, Alexander 
and Birchall, Lindsay J. and Mullan, Aoibheann F. and 
Su, Kim and Pearmain, Laurence and Dolman, Grace 
and Zaitoun, Abed M. and Friedman, Scott L. and 
MacDonald, Andrew and Irving, William L. and Guha, 
Indra N. and Hanley, Neil A. and Hanley, Karen Piper 
(2017) SOX9 predicts progression towards cirrhosis in 
patients while its loss protects against liver fibrosis. 
EMBO Molecular Medicine, 9 (12). pp. 1696-1710. ISSN 
1757-4684 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/46609/9/emmm.201707860.full.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
This article is made available under the Creative Commons Attribution licence and may be 
reused according to the conditions of the licence.  For more details see: 
http://creativecommons.org/licenses/by/2.5/
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
Research Article
SOX9 predicts progression toward cirrhosis in
patients while its loss protects against liver fibrosis
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Abstract
Fibrosis and organ failure is a common endpoint for many chronic
liver diseases. Much is known about the upstream inflammatory
mechanisms provoking fibrosis and downstream potential for
tissue remodeling. However, less is known about the transcrip-
tional regulation in vivo governing fibrotic matrix deposition by
liver myofibroblasts. This gap in understanding has hampered
molecular predictions of disease severity and clinical progression
and restricted targets for antifibrotic drug development. In this
study, we show the prevalence of SOX9 in biopsies from patients
with chronic liver disease correlated with fibrosis severity and
accurately predicted disease progression toward cirrhosis. Inacti-
vation of Sox9 in mice protected against both parenchymal and
biliary fibrosis, and improved liver function and ameliorated
chronic inflammation. SOX9 was downstream of mechanosignaling
factor, YAP1. These data demonstrate a role for SOX9 in liver
fibrosis and open the way for the transcription factor and its
dependent pathways as new diagnostic, prognostic, and therapeu-
tic targets in patients with liver fibrosis.
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Introduction
In response to inflammation, the secretion of collagen-rich patholog-
ical extracellular matrix (ECM) by liver myofibroblasts, called
hepatic stellate cells (HSCs), destroys normal tissue architecture and
causes fibrosis. Fibrosis occurs in both hepatic parenchymal and
biliary diseases and is a major cause of morbidity and mortality
against which there are no approved drug treatments (Iredale, 2007;
Friedman, 2008; Lee & Friedman, 2011; Lee et al, 2015). Even after
withdrawal of the inflammatory insult, fibrosis can progress
unchecked to organ failure and death. Alternatively, in some indi-
viduals liver fibrosis may not advance despite persisting insult (Ellis
& Mann, 2012; Kisseleva et al, 2012; Troeger et al, 2012). Address-
ing this uncertainty requires in vivo knowledge of the molecular
mechanisms that regulate fibrosis.
The transcription factor sex determining region Y box 9 (SOX9)
is responsible in vivo for the organized deposition of collagen as part
of cartilage formation. In humans, mutations in the SOX9 gene
cause the haploinsufficiency disorder campomelic dysplasia (CD),
characterized by failed chondrogenesis (Foster et al, 1994; Wagner
et al, 1994; Pritchett et al, 2011). In the liver, SOX9 is ordinarily
expressed in cholangiocytes lining the bile ducts and plays roles in
bile duct development and in hepatic regeneration (Antoniou et al,
2009; Carpentier et al, 2011; Yanger et al, 2013; Tarlow et al, 2014;
Font-Burgada et al, 2015; Jors et al, 2015; Lu et al, 2015). In vitro,
we have shown that SOX9 becomes expressed during the activation
of HSCs by profibrotic signaling factors when it promotes
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production of ECM components, such as type 1 collagen (COL1) and
osteopontin (OPN) (Hanley et al, 2008; Pritchett et al, 2012).
However, these studies relied on imperfect in vitro cell models.
Direct in vivo evidence for SOX9 function in liver fibrosis (rather
than regeneration) has been lacking.
In this study, we have studied SOX9 in patients with chronic liver
disease where sequential liver biopsies enabled fibrosis severity and
disease progression to be deciphered over time and examined the
consequences of inactivating SOX9 in rodent models of parenchymal
and biliary liver fibrosis.
Results
SOX9 profile in the liver of patients with chronic liver disease
Patients chronically infected with hepatitis C virus (HCV) show vari-
able severity of liver fibrosis with the potential for marked disease
progression within a few years. While these patients are now routi-
nely treated with antiviral drugs, this clinical setting offered a
distinctive opportunity to study SOX9 and fibrosis progression
because previous routine surveillance entailed patients undergoing
accurately staged serial biopsies from their liver. We accessed the
UK Trent HCV Cohort and identified 115 patients with initial and
follow-up biopsy categorized for severity by a histopathologist using
the 7-point Ishak (IS) fibrosis stage, IS0 to IS6; the latter represent-
ing the most severe fibrosis/cirrhosis (Ishak et al, 1995)
(Table EV1). 70% of patients had no or mild fibrosis on initial
biopsy (IS0-1; n = 80) rather than more intermediate (IS2-3; 16%,
n = 19) or severe disease (IS4-6; 14%, n = 16). However, at follow-
up biopsy 36.9  2.5 months later, this percentage declined to 54%
(n = 62) with corresponding increases in both the IS2-3 category
(24%, n = 28) and severe (22%, n = 25) fibrosis. Thus, over
3 years liver fibrosis had progressed in 30 patients (26%), regressed
in eight patients (7%), and remained unchanged in 77 (67%) allow-
ing us to correlate SOX9 with severity (tissue remained from 152
biopsies for this purpose; Fig EV1) and disease progression (where
tissue remained from 59 paired biopsies; Fig EV1).
Staining for collagen using picrosirius red (PSR) and aSMA (a
marker of activated myofibroblasts) was increased with higher Ishak
fibrosis stage particularly in regions of scarring (Fig 1A and B). In
IS0 (no liver fibrosis), SOX9 was observed in the nuclei of cholan-
giocytes (Fig 1B; Antoniou et al, 2009; Rowe et al, 2013). In moder-
ate and severe fibrosis, nuclear SOX9 was progressively more
noticeable in cells with elongated nuclei and aSMA. SOX9 was also
detected at slightly lower levels in cells with large round nuclei adja-
cent to the scar costained for the hepatocyte marker, a1-antitrypsin
(a1AT), consistent with regenerative hepatocytes (termed Hep from
here on) (Fig 1B and C). SOX9 was present in all CK19+ and CK7+
cholangiocytes lining bile ducts; these cells were not detected
outside of duct structures. SOX9 was not detected in the CD34+
vasculature. Given the role of SOX9 in regenerative hepatocytes
(Kawaguchi, 2013), we studied EpCAM which marks cholangiocytes
and nascent hepatocytes (Yoon et al, 2011) and compared this to
the SOX9+ ductal plate in human fetal liver, which gives rise to peri-
portal hepatocytes and biliary cells (Carpentier et al, 2011;
Furuyama et al, 2011; Rowe et al, 2013). In moderate and severe
fibrosis, EpCAM localized to the SOX9+ Heps adjacent to the scar in
an arrangement remarkably similar to the fetal ductal plate (Fig 1D).
Thus, SOX9 could be partitioned discretely into bile duct nuclei and
post-injury expression in isolated cells demarcating a putative HSC/
Hep population.
SOX9 index correlates with severity of liver fibrosis in patients
and predicts progression
We used the above profiles to construct a SOX9 index of positive
nuclei per surface area of biopsy. We counted the biliary, HSC/Hep,
and total SOX9+ populations in 152 biopsies. While there was no
change in SOX9+ biliary cells at different stages of fibrosis, the
HSC/Hep SOX9 index doubled as fibrosis severity increased; a
finding which was also reflected in the total count (Fig 1E). HSC/
Hep and total SOX9 indices from the initial biopsies correlated very
strongly with the increment in Ishak fibrosis stage between initial
and follow-up biopsies, while the biliary count did not alter
(Fig 1F). The HSC/Hep SOX9 index was progressively higher for
those patients whose liver fibrosis worsened over the subsequent
3 years. To see whether we could detect mild disease that was
destined to progress, we identified all patients whose initial biopsy
was IS0-2 and classified them into two groups: “progressors”
(n = 12), defined by a worsening fibrosis at follow-up biopsy of ≥ 2
Ishak stages; or “non-progressors” (n = 25) where the fibrosis either
improved was static or worsened by no more than one stage.
Patients across the two groups had not received anti-HCV treatment,
showed no significant difference in age, gender, alcohol consump-
tion, ethnicity, serum alanine aminotransferase (ALT), necroin-
flammation, or HCV genotype (Appendix Table S1). In contrast, the
HSC/Hep SOX9 index was significantly increased, more than
double, in the initial biopsy of the “progressors” compared to “non-
progressors” (P < 0.01; Fig 1G). The potential to predict future
progression was analyzed by calculating the area under the receiver
operating characteristic curve (AUROC). The ideal test would have
an AUROC of 1, where a random guess would have an AUROC of
0.5. The HSC/Hep SOX9 index (AUROC = 0.895, P < 0.001), and
consequently the total SOX9 index (AUROC = 0.910, P < 0.05), fore-
cast significant worsening of fibrosis amongst patients in the
“progressor” category (Fig 1H). Moreover, when the initial biopsy
was subdivided into individual Ishak stages (rather than an amalga-
mated IS0-2) or into gender, the total SOX9 index significantly
predicted progression in each instance except for patients at IS2
where low numbers were limiting (Appendix Table S2). We deter-
mined positive and negative predictive values (PPV and NPV)
around the mean SOX9 count for total, HSC/Hep, and biliary popu-
lations (Fig 1I–K). The HSC/Hep and total SOX9 indices were
predictive (Fig 1I and J), while the biliary count was unhelpful
(Fig 1K). For additional comparison, we also quantified necroin-
flammation (NI) using the 0–18 scale of minimal (1–3), mild (4–8),
moderate (9–12), and severe (13–18) NI (Ishak et al, 1995). The
mean NI score in the initial biopsy was 2.75. Applying this threshold
gave a PPV of 67% (NPV 63%). Setting the threshold at the upper
limit of mild NI (score = 8) excluded all except one patient (Fig 1L;
i.e., less predictive than the HSC/Hep and total SOX9 indices).
Univariate logistic regression analysis identified age, the HSC/
Hep (or total) SOX9 count, and NI to be significant risk factors in
disease progression (Table 1; P < 0.05). However, when adjusted
for time between biopsies using multivariate analysis, only age and
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the SOX9 index retained significance. The odds ratios indicated that
each 1-year increase in age was associated with a 4% increase in the
risk of becoming a “progressor”, whereas each cell increase in either
the HSC/Hep or total SOX9 index increased the risk of fibrosis
progression by 12% (Table 1). Male gender, serum ALT levels, or NI
at first biopsy did not associate significantly with fibrosis progression.
Sox9 is induced in HSCs by liver injury and its loss protects
against fibrosis and chronic inflammation
To investigate the mechanism underlying SOX9 function in liver
fibrosis, we explored the consequence of its loss in two well-estab-
lished rodent models of the disease. Liver fibrosis was induced by
carbon tetrachloride (CCl4) (with olive oil control) injections given
twice weekly for 8 weeks to induce parenchymal disease or the bile
duct ligated (BDL) to cause peribiliary fibrosis at 2 weeks. While
SOX9 persisted in cholangiocytes, the nuclear transcription factor
became detected in both models in a subset of HNF4a+ cells with
large round nuclei scattered around the bile ducts, equivalent to the
regenerative Heps observed in human tissue (Fig 2A and B, and
Appendix Fig S1). SOX9 protein and mRNA were detected in aSMA-
positive spindle-shaped cells in sections of liver fibrosis induced by
CCl4 and BDL (Fig 2C) as previously (Hanley et al, 2008; Pritchett
et al, 2012). To corroborate that these cells were indeed activated
HSCs, we isolated HSCs following acute liver injury with CCl4 (i.e.,
before scarring interferes with the HSC isolation procedure) and
showed without culture that SOX9 was increased compared to
control (Fig 2D and Appendix Fig S2). This ex vivo isolation from
fibrotic liver has led to these cells being termed “in vivo activated”
HSCs (De Minicis et al, 2007; Mederacke et al, 2015; Martin et al,
2016). Taken together, these data were entirely consistent with our
observations in fibrotic human liver (Fig 1).
Sox9 null mice develop severe developmental defects and die in
the perinatal period (Pritchett et al, 2011). Therefore, we used
tamoxifen (Tam) to remove SOX9 expression in Sox9fl/fl;ROSAC-
reER+/ adult mice with Sox9fl/fl;ROSACreER animals as control.
Tamoxifen was injected twice in the week prior to fibrosis induction
in both BDL and CCl4 models and every 2 weeks during the 8-week
regime of CCl4 injury. Tamoxifen effectively excised the Sox9 gene
and removed SOX9 protein (Fig 2E and Appendix Fig S3). Removal
of SOX9 in adult mice did not compromise survival (corroborated
by others Mori-Akiyama et al, 2007). Tamoxifen did not induce
ectopic SOX9 expression in uninjured control livers (Appendix Fig
S3) or alter SOX9 detection in the HSC/Hep and biliary compart-
ments of injured control livers. Knocking out Sox9 did not alter
the liver/body weight ratio in uninjured or fibrotic settings
(Appendix Fig S4). In both parenchymal and peribiliary models,
fibrosis was clearly improved by loss of Sox9 with reduced
◀ Figure 1. SOX9 in human liver fibrosis.A Liver biopsies showing no (IS0), moderate (IS3), and severe (IS6) fibrosis stained by PSR. Size bar, 300 lm.
B Immunohistochemistry (brown staining) for aSMA and SOX9 on consecutive sections from patients with no (IS0), moderate (IS3), and severe (IS6) fibrosis. Boxed
areas are shown to the right at higher magnification. Bile duct (bd). SOX9 detected in HSCs with elongated nuclei (hatched line) next to scar and in hepatocytes
with rounded nuclei (arrows). Size bars, 200 lm.
C Immunofluorescence for SOX9 (red) costained with CK19, CK7, a1AT, and aSMA (green). Arrowheads show elongated nuclei in aSMA-positive HSCs.
D Immunohistochemistry for SOX9 and EpCAM (brown staining) on consecutive sections from severe (IS6) fibrosis and normal fetal liver at 18 weeks post-conception
(wpc). Dual immunofluorescence confirms SOX9 and EpCAM in the same cell in severe fibrosis.
E–G Data for SOX9 index for the biliary, HSC/Hep, and total (biliary + HSC/Hep) populations. In worsening categories of liver fibrosis (E). In the initial biopsy plotted
against the increment in Ishak fibrosis stage between the initial and follow-up biopsy (F). The lines show the best fit by ordinal logistic regression analysis. In the
initial biopsy categorized by whether patients did or did not progress by at least two stages on follow-up biopsy (G).
H Receiver operator curves for the sensitivity and specificity of the SOX9 index in the initial biopsy as a predictor of non-progressors and progressors.
I–L Plots of SOX9 index (total, HSC/Hep, and biliary) and NI score marking progressors in green and non-progressors in red. The solid line indicates the mean in each
graph. The broken line in NI dot plot (L) indicates the threshold (score = 8) below which all NI is categorized as “mild”.
Data information: Unless otherwise indicated in text, two-tailed unpaired t-test was used for statistical analysis. Data in bar charts show means  s.e.m. P-values are
indicated. Sample numbers for (E and F) (n = 152); (G), non-progressors (n = 25) and progressors (n = 12).
Table 1. Logistical regression analysis indicating risk factor association with progression of liver fibrosis.
Predictor
Odds ratio (95% CI)
Unadjusted Adjusted for age Adjusted for time to progression
Age, per year increase 1.08 (1.00, 1.17)* – 1.04 (1.00, 1.08)*
Age, > 55 versus ≤ 55 years 4.36 (0.36, 53.39) – –
Gender, male versus female 3.09 (0.56, 17.17) 3.32 (0.50, 21.92) 2.87 (0.44, 18.70)
Total Sox9, per unit increase 1.13 (1.04, 1.23)* 1.13 (1.03, 1.23)* 1.12 (1.03, 1.22)*
Sox9 isolated cells, per unit
increase
1.13 (1.04, 1.23)* 1.14 (1.04, 1.25)* 1.12 (1.03, 1.23)*
Sox9 BD, per unit increase 1.14 (1.00, 1.29)* 1.14 (0.99, 1.31) 1.09 (0.95, 1.25)
ALT, per unit increase 1.01 (0.99, 1.02) 1.01 (0.99, 1.02) 1.01 (0.99, 1.02)
NI, per unit increase 1.63 (0.98, 2.71)* 1.55 (0.90, 2.68) 1.68 (0.94, 3.01)
*Significant association (P < 0.05).
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deposition of collagen by PSR staining and less surface area covered
by aSMA staining (Fig 3A–F). Liver function, assessed by serum
biochemistry, was also markedly improved, especially in the BDL
model in which serum ALT and bilirubin were normalized (Fig 3G
and H). In patients with parenchymal liver injury, scars which
extend from one portal tract to another are termed “bridging
fibrosis” and, when numerous, are a marker of severity (Ishak
fibrosis score ≥ 4 on the IS0-6 7-point scale) (Ishak et al, 1995). Loss
of SOX9 reduced the incidence of bridging fibrosis induced by CCl4
injury by at least one-third (Fig 3I), while in BDL, bile duct
A
C E
D
B
Figure 2. SOX9 is involved in liver fibrosis in vivo.
A Immunohistochemistry for SOX9 (brown) in wild-type (WT) mice following CCl4- or BDL-induced fibrosis. SOX9-positive bile ducts (bd) and hepatocytes (arrowheads)
indicated.
B (Left panel) Immunofluorescence for SOX9 (green) and HNF4a (red) in WT fibrotic mice. Arrowheads (orange/yellow staining) indicate SOX9+/HNF4a+ hepatocytes,
and star (*; red) indicates SOX/HNF4a+ hepatocytes. (Right panel) Immunofluorescence for SOX9 (green nucleus) and CK19 (red cytoplasm) in WT fibrotic mice.
Arrowheads (green) indicate SOX9+ hepatocytes, and star (*) indicates SOX hepatocytes identified by DAPI staining in Appendix Fig S1.
C Co-localization by immunohistochemistry (top panel) and in situ hybridization (lower panel) for SOX9 (red) and aSMA (brown) in wild-type (WT) mice following
CCl4- or BDL-induced fibrosis.
D Expression of SOX9 protein by immunoblotting of in vivo activated HSCs extracted from WT mice following CCl4 injections compared to olive oil control.
E Immunohistochemistry for SOX9 (brown) in control (Sox9fl/fl;RosaCreER) or Sox9-null (Sox9fl/fl;RosaCreER+) mice following fibrosis. Bile ducts (bd) and hepatocytes
(arrowheads) indicated. SOX9 is absent, even in bile ducts in Sox9-null liver.
Data information: Size bar, 25 lm (A, B and E), 10 lm (C).
Source data are available online for this figure.
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Figure 3. Loss of Sox9 improves liver fibrosis in vivo.
Representative images and quantification shown for olive oil-treated (n = 6) or chronic CCl4 (n = 5 Sox9
fl/fl;RosaCreER; n = 8 Sox9fl/fl;RosaCreER+)-induced fibrosis or
following sham operation (n = 5) or BDL (n = 7 Sox9fl/fl;RosaCreER; n = 5 Sox9fl/fl;RosaCreER+))-induced fibrosis.
A Picrosirius red (PSR) staining (collagen deposition in red) counterstained with fast green (top row) and immunohistochemistry for a-SMA (brown staining bottom
row; activated HSC/myofibroblast marker) in olive oil-treated (left) or chronic CCl4-induced fibrosis (right) in control and Sox9-null mice. Size bars = 200 lm.
B, C Quantification of surface area covered by the PSR staining or a-SMA in control (Cnt) and Sox9-null (Null) in (A).
D PSR staining (red; top row) and immunohistochemistry for a-SMA (brown; middle row) and CK19 (brown; bottom row) in control and Sox9-null mice following
Sham operation (left) or BDL-induced fibrosis (right). Size bars = 500 lm.
E, F Quantification of surface area covered by the PSR staining or a-SMA in (D).
G, H Liver function is improved in Sox9-null mice following CCl4 (G)- or BDL (H)-induced fibrosis compared to control mice. Reduction in serum alanine
aminotransferase (ALT; G, H) and bilirubin (H) down to levels shown in non-fibrotic mice (olive oil-treated groups; oil).
I Sox9 loss improved severity of fibrosis compared to control mice indicated by quantification of bridging fibrosis in PSR sections following CCl4. Olive oil-treated
mice had no bridging fibrosis, in line with a non-fibrotic liver histology in (A).
J Ductal hyperplasia as quantified by the surface area covered by CK19-positive ducts in (D) is reduced in Sox9-null mice compared to control following BDL.
Data information: All mice were treated with tamoxifen (Tam) which did not induce ectopic expression of SOX9 in non-fibrotic livers (Fig 2A and E, and Appendix Fig S3).
All experiments are n ≥ 5 as indicated. Two-tailed unpaired t-test was used for statistical analysis. Data in bar charts show means  s.e.m. P-values indicated.
EMBO Molecular Medicine ª 2017 The Authors
EMBO Molecular Medicine SOX9 predicts liver fibrosis progression Varinder S Athwal et al
6
Published online: November 6, 2017 
hyperplasia (assessed by surface area immunostained for CK19) was
halved (Fig 3J). In both CCl4 and BDL models, tissue architecture
was improved by H&E histology staining and, in keeping with our
previous work (Hanley et al, 2008; Pritchett et al, 2012, 2014;
Martin et al, 2016), profibrotic COL1 expression was greatly reduced
in response to Sox9 loss in vivo and in vitro (Appendix Figs S5–S7).
Given the critical developmental role for SOX9 in multiple tissues
(Pritchett et al, 2011), it was not possible to knock out SOX9 in
HSCs using the currently published PdgfrB, AP2, and LRAT Cre
models (Henderson et al, 2013; Mederacke et al, 2013; Moran-
Salvador et al, 2013). PdgfrB expression overlaps SOX9 in neural
crest cell (NCC) populations responsible for heart development
(Akiyama et al, 2004; Van den Akker et al, 2008; Smith & Tallquist,
2010). In keeping with this, > 80% of our Sox9fl/fl;PdgfrBCre+ mice
died at birth. AP2 also has a major role in NCCs (and chondrogene-
sis) (Wenke & Bosserhoff, 2010; Pritchett et al, 2011). LRAT expres-
sion overlaps SOX9 during development [e.g., in liver, lung,
pancreas (Batten et al, 2004; Jennings et al, 2013; Pritchett et al,
2011)]. Thus, none of these Cre drivers were suitable for HSC-
specific SOX9 inactivation. In light of this, to determine which of the
three SOX9+ liver cell types (cholangiocyte, HSC, and/or Hep)
harbored the transcription factor’s profibrotic function we took
advantage of an AlbuminCre (AlbCre) allele to generate Sox9fl/fl;
AlbCre+/ mice, which excised Sox9 from hepatocytes and cholan-
giocytes (both lineages develop from Alb+ progenitors) but not
HSCs (Fig 4A and B, and Appendix Figs S8 and S9). Uninjured adult
animals were healthy with normal hepatic and biliary function as
expected (Poncy et al, 2015). Fibrotic ECM deposition in Sox9fl/fl;
AlbCre+/ mice was as extensive as in control mice in both chronic
CCl4 and BDL models (Fig 4C–E). The liver/body weight ratio was
unaltered (Appendix Fig S10). Surface area covered by aSMA stain-
ing was no different (Appendix Fig S11). SOX9 protein remained in
discrete elongated cells in Sox9fl/fl;AlbCre+/ mice, and transcript
was localized to aSma+ cells (Fig 4A and B, and Appendix Fig S8).
To further demonstrate retention of SOX9 in the HSC lineage,
in vitro activation of HSCs from Sox9fl/fl;AlbCre+/ livers showed
normal induction of SOX9 protein (Fig 4F and G, and Appendix Fig
S9). From these combined data in Sox9fl/fl;ROSACreER+/ and
Sox9fl/fl;AlbCre+/ mice, we conclude that SOX9’s major profibrotic
function is in HSCs.
Next, we explored the effect of eliminating SOX9 expression on
chronic inflammation in liver fibrosis. In mice, there is a natural
tendency for liver fibrosis to resolve after cessation of CCl4 injury
reliant on a phenotypic switch in monocyte-derived liver macro-
phages from high (profibrotic) to low (“restorative”) Ly6C expres-
sion (Ramachandran et al, 2012). This observation was maximal
72-h post-CCl4 injection amongst an F4/80
+ cell population
(Ramachandran et al, 2012). To probe this further, we isolated the
monocyte–macrophage lineage (Ly6C+CD64+) from the wider pool
of CD45+CD11B+ myeloid cells 72 h after conclusion of a 4-week
program of biweekly CCl4 injections (Appendix Fig S12). The
fibrotic livers from control and Sox9 null mice contained four
distinct populations according to levels of Ly6C and MHCII, a speci-
fic macrophage marker (Fig 5A and B, and Appendix Fig S12).
Populations 1 and 2 with intermediate or high Ly6C levels lacked
macrophage maturity markers (MerTK, CD64, and F4/80) consistent
with infiltrating monocytes (Fig 5A and B). Population 3 (MHCII+-
Ly6CHi/Int) contained a proportion of cells positive for MerTK,
CD64, and F4/80, while virtually all population 4 (the Ly6CLow cells)
expressed high levels of the macrophage maturity markers (Fig 5A
and B). In fibrotic livers from control mice, sorting by F4/80+ identi-
fied more Ly6CLow than Ly6CHigh/int cells consistent with previous
work (Ramachandran et al, 2012; Fig 5C). However, by MHCII
sorting, the proportion of Ly6CHi/+ and Ly6CInt/ cells were equiva-
lent (Fig 5D and E). Against this backdrop, we scrutinized chronic
inflammation in the tamoxifen-treated Sox9fl/fl;ROSACreER+/mice.
The size of the monocyte–macrophage infiltrate in the liver was
similar [i.e., the sum of populations 1–4 was unchanged (Fig 5D and E)].
However, populations 1 and 2 were expanded, while populations
3 and 4 were diminished (visible in Fig 5A and B and quantified in
Fig 5D and E). The intensity of F4/80 immunostaining was
also reduced in the absence of SOX9 (Fig 5F). As SOX9 is not
expressed in the hematopoietic lineage, the implications of these
data are twofold: that monocyte recruitment following injury is
unaffected; however, in the context of SOX9-dependent reduced
scarring and improved liver function, maturation of macrophages is
blocked.
Mechanosensitive signaling regulates SOX9 via YAP1 during
liver fibrosis
We have previously shown SOX9 is induced by the key profibrotic
signaling factors transforming growth factor beta (TGF-b) and
hedgehog (HH). To explore this further, we reasoned that upregu-
lated SOX9, and consequently increased ECM deposition, in fibrotic
liver might relate to tissue stiffness. Therefore, we extracted HSCs
and cultured them on acrylamide hydrogels to model normal liver
elasticity or the fibrotic environment at 4 or 12 kPa, respectively.
Yes-associated protein-1 (YAP1) is a mechanosensitive transcription
factor that when dephosphorylated is nuclear and active with
co-factors, transcriptional coactivator with PDZ-binding motif (TAZ,
also known as WWTR1) and TEA domain factor (TEAD). In
contrast, when phosphorylated, YAP1 is cytoplasmic and inactive.
In HSCs cultured on 4 kPa hydrogels, YAP1 was cytoplasmic, SOX9
not detected, and aSMA, TAZ, and TEAD only weakly present
(Fig 6A and B). In stark contrast, under the 12 kPa conditions
modeling fibrosis, YAP1, TAZ, and TEAD were robustly detected in
the nucleus with cytoplasmic aSMA (Fig 6A and B). Moreover, when
YAP1:TEAD complexes were disrupted using their specific inhibitor,
verteporfin, SOX9 protein levels were reduced by 60% in activated
HSCs (Fig 6C). Previous studies by us and others have shown that
verteporfin improves aspects of liver fibrosis in vivo (Mannaerts
et al, 2015; Martin et al, 2016). In the setting of verteporfin
treatment, SOX9 counts were reduced in the HSC/Hep compartment
in both CCl4-induced liver injury and BDL (Fig 6E and F).
Discussion
SOX9 is a key transcription factor regulating multiple components of
the ECM during normal development and in studies modeling
isolated HSC function in vitro (Hanley et al, 2008; Pritchett et al,
2012). Here, we studied the requirement for SOX9 in vivo in liver
fibrosis. Several conclusions can be drawn. Firstly, loss of SOX9
in vivo abrogated fibrosis in response to liver injury. SOX9 expres-
sion was restricted to cholangiocytes, and post-injury HSCs and
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AB
C
F G
D
E
Figure 4. Fibrosis in Sox9fl/fl;AlbCre+/ mice.
A–C Representative images shown for olive oil-treated (n = 5) or chronic CCl4 (n = 5)-induced fibrosis or following sham operation (n = 6 Sox9
fl/fl;AlbCre; n = 5 Sox9fl/fl;
AlbCre+) or BDL (n = 5 Sox9fl/fl;AlbCre; n = 8 Sox9fl/fl;AlbCre+)-induced fibrosis. SOX9 immunohistochemistry (brown; A), in situ hybridization for Sox9 (brown) and
a-Sma (red) and collagen deposition by PSR staining (red; B) in control (Sox9fl/fl;AlbCre) or Sox9-null (Sox9fl/fl;AlbCre+) mice following fibrosis. Higher magnified
image of SOX9 localization in discrete cells within the scar is shown for CCl4 and BDL in the Sox9
fl/fl;AlbCre+ mice (A).
D, E Quantification of surface area covered by the PSR staining in (C).
F Expression of SOX9 protein by immunohistochemistry in quiescent (Q) and activated (A) HSCs extracted from Sox9fl/fl;AlbCre+ mice.
G Individual fluorescent channels showing localization and expression of a-SMA (left panel), SOX9 (middle panel), and composite image for a-SMA (green) and SOX9
(red) in right panel in activated Sox9fl/fl;AlbCre+ HSCs (genotyping shown in Appendix Fig S9).
Data information: Two-tailed unpaired t-test was used for statistical analysis. Data in bar charts show means  s.e.m. Size bars = 100 lm (A), 10 lm (B) 200 lm (C),
25 lm (G).
Source data are available online for this figure.
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some hepatocytes (most likely regenerative). There was no
impact from eliminating SOX9 in hepatocytes and cholangiocytes
[which furthers the argument against epithelial-to-mesenchymal
transition as a significant mechanism for liver fibrosis (Scholten
et al, 2010; Taura et al, 2010; Wells, 2010)]. Our data point toward
the HSC as the causative cell type-mediating fibrosis and that this
lineage emerges separately from albumin-expressing hepatobiliary
precursors (Yin et al, 2013). Unaltered biliary hyperplasia in our
A
B
C
F
D E
Figure 5. Ly6Clow pro-resolution macrophages predominate in Sox9-null animals.
A, B Flow cytometry of CD45+ CD11B+ cells in control (Sox9fl/fl;RosaCre; A) and Sox9-null (Sox9fl/fl;RosaCre+; B) livers stained for Ly6C and MHCII (far left) to identify
four populations of cells with differences in their expression of MerTK, CD64, F4/80, and MHCII.
C Graphical representation of Ly6C and F4/80 staining in macrophages from populations 3 and 4.
D, E Graphical representation of cell numbers in the four Ly6C and MHCII cell populations in control and Sox9-null livers. Data are representative of four independent
experiments.
F F4/80 immunohistochemistry (brown staining) in control and Sox9-null mice livers following 4-week CCl4-induced fibrosis. Size bar = 100 lm.
Data information: Two-tailed unpaired t-test was used for statistical analysis. Data in bar charts show means  s.e.m. P-values indicated. All experiments are n = 4.
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injured Sox9fl/fl;AlbCre+/ mice also implies that SOX9 is not an
intrinsic requirement for post-injury proliferation of cholangiocytes.
To translate, the functional requirement for SOX9 in fibrosis
from mouse to human is challenging. Genetic evidence in human
would require inactivating mutations or haploinsufficiency
protecting against liver fibrosis, but campomelic dysplasia is a
multisystem disorder lethal around birth (Foster et al, 1994;
Wagner et al, 1994). Activating mutations or duplications of the
A C
D
E
F
B
Figure 6. YAP signaling regulates SOX9.
A, B Immunofluorescence of activated mouse HSCs cultured on plastic (A) or hydrogels (A, B). Individual fluorescent channels showing localization and expression of
SOX9 (left), YAP (middle), and composite image for SOX9 (red) and YAP (green) in right panel. (B) Individual and composite images for aSMA (green) and TAZ (red) or
TEAD (red). Size bars, 25 lm.
C Quantified decrease in SOX9 protein levels following inhibition of YAP using verteporfin (VP) in activated mouse HSCs expressed relative to DMSO control (n = 3).
D Immunohistochemistry for SOX9 (brown) following CCl4- or BDL-induced fibrosis in mice treated with DMSO (CCl4 n = 4, BDL n = 7) or verteporfin (CCl4 n = 3, BDL
n = 5). Size bar, 50 lm.
E, F Quantification of SOX9 cell numbers in the HSC/Hep population.
Data information: Two-tailed unpaired t-test was used for statistical analysis. Data in bar charts show means  s.e.m. P-values are indicated.
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SOX9 locus (a cause of 46,XX disorder of sex development) that
might promote liver fibrosis are exceptionally rare and lack the
additional context of liver injury. Our data on a cohort of patients
with serial biopsies over time and variable fibrosis progression
(Ghany et al, 2009; Liang & Ghany, 2013) provide three strands
of evidence that SOX9’s role in liver fibrosis in mouse seems
likely in human: The profile of SOX9 detection following liver
injury in patients was identical to that observed in mouse; the
prevalence of de novo SOX9 expression in biopsies correlated
precisely with fibrosis severity; and thirdly, the extent of SOX9 at
early stages of disease predicted progression within 3 years.
Indeed, the SOX9 index performed better than other fibrosis risk
factors and could potentially assist the stratification of patients
with liver fibrosis alongside other measures, such as the cirrhosis
risk score (Huang et al, 2007; Marcolongo et al, 2009; Trepo
et al, 2011).
Taken together, our data support a model whereby injury
induces SOX9 downstream of YAP1 in HSCs to promote liver
fibrosis. Our data open up the potential for SOX9 and its dependent
pathways as biomarkers or as targets for lessening liver scarring,
improving hepatic chronic inflammation and halting the progression
of liver fibrosis toward cirrhosis.
Materials and Methods
Study design
The goal of this study was to provide comprehensive evidence
in vivo in mouse and human that the transcription factor SOX9
and its associated pathways promote liver fibrosis and its
progression toward cirrhosis. All experiments were blinded to
the person analyzing the data. For animal experiments, where
possible, the minimum number of animals per fibrosis protocol
was five based on accepting an 80% chance of detecting a 30%
change in collagen content from normal versus fibrotic animals
at the level of P ≥ 0.05. However, where additional animals have
been available, we have included these in our analysis to
improve power and our ability to statistically detect smaller
physiological effects.
For all human studies, informed consent was obtained from all
subjects (including embryonic and fetal tissue) and experiments
conformed to the principals set out in the WMA Declaration of
Helsinki and the Department of Health and Human Services
Belmont Report.
Animal experiments
All mouse strains were maintained on a C57BL/6J background in a 12-
h light–dark cycle with water and food provided ad libitum. Sox9fl/fl
mice were a kind gift from Professor Gerd Scherer (Kist et al, 2002).
RosaCreER (Seibler et al, 2003) and AlbuminCre (Postic et al, 1999)
were purchased from Jackson Laboratories. To allow inducible global
Sox9 deletion, Sox9fl/fl mice were crossed with RosaCreER mice to
generate Sox9fl/fl;RosaCreER animals. To delete Sox9 in cholangiocytes
and hepatocytes, Sox9fl/fl mice were crossed with AlbCre mice to give
Sox9fl/fl;AlbCre+/ animals. REDExtract-N-AMPTM Tissue PCR kit
(Sigma, UK) was used to genotype DNA prepared from ear clips. Three
primers were used to detect Sox9 floxed alleles and recombination
events (Reverse: CGCTGGTATTCAGGGAGGTACA; F1: CTCCGGTAG
CAAAGGCGTTTAG; F2: CCGGCTGCTGGGAAAGTATATG). Reverse
and F1 gave a 314-bp product only if recombination had occurred.
Reverse and F2 gave either a 247-bp product (wild type) or a 419-bp
(floxed allele) product (Kist et al, 2002). For RosaCreER genotyping,
forward (CCATCATCGAAGCTTCACTGAAG) and reverse (GGAGTTT
CAATACCCGAGATCATGC) primers gave a 310-bp product. To keep
the possibility of spontaneous Cre activity in the absence of tamoxifen
to a minimum, only RosaCreER heterozygote animals were used. To
allow detection of the wild-type Rosa26 allele and to confirm animals
were heterozygous wild type, forward (CATGTCTTTAATCTACCTC
GATGG) and reverse primers (CTCTTCCCTCGTGATCTGCAACTCC)
were used to give a 299-bp product. To delete Sox9 in cholangiocytes
and hepatocytes, Sox9fl/fl mice were crossed with AlbCre mice to give
Sox9fl/fl:AlbCre+/ animals. Only heterozygous animals were used,
and genotype was confirmed using three primers (common Cre
reverse: TCGTTGCATCGACCGGTAAT; Albumin gene reverse:
TAGCATGGTCGAGCAGGCAG; Albumin promoter forward: AGAGC
GAGTCTTTCTGCACACAG) which gives a 430-bp product in the pres-
ence of the wild-type albumin allele and a 200-bp product in the pres-
ence of the AlbCre allele.
Animals were housed and maintained and animal experiments
performed under approval from the University of Manchester Ethi-
cal Review Committee and in accordance with UK Government
Home Office license for animal research. Carbontetrachloride (CCl4)
or bile duct ligation (BDL) was used to induce chronic liver fibrosis
in age-matched male mice (between 8 and 14 weeks old at the start
of experiments), and YAP signaling was interrogated during fibrosis
using verteporfin (VP) (Sigma, UK) as previously described (Martin
et al, 2016). All randomly assigned experimental and controls were
littermate sex- and age-matched mice.
For CCl4 fibrosis was induced by 2-ll intraperitoneal (i.p.)
injections of sterile CCl4 (Sigma, UK) per g body weight in a ratio
of 1:3 by volume in olive oil, or olive oil alone (control) twice
weekly for 8 weeks. Tissue and serum were collected at the end
of the experiments. For BDL-induced fibrosis, under anesthesia
two ligatures were placed around the exposed bile duct. Sham
(control) animals underwent the same procedure without ligation
of the bile duct. To improve post-operative survival, animals were
kept in a thermoneutral warm cabinet (30°C) following BDL, and
given soaked diet. Tissue and serum were collected 14 days after
surgery.
To induce activation of Cre and global deletion of Sox9 in Sox9fl/fl;
RosaCreER animals, tamoxifen (Sigma, UK) was given by i.p injec-
tion. To control for any unexpected effects of tamoxifen, both Sox9fl/fl;
RosaCreER+/ and Sox9fl/fl;RosaCreER/ animals were injected. For
CCl4, 4 mg tamoxifen (20 mg/ml in olive oil) was injected 8 and
7 days before the first CCl4 injection (Day 0). Subsequent 2 mg doses
were given fortnightly, starting on day 6, for the duration of the exper-
iment. For BDL, 4 mg tamoxifen (20 mg/ml in olive oil) was injected
i.p. 8 and 7 days prior to surgery. 2 mg was injected i.p. 7 days after
surgery.
For both CCl4 and BDL models of fibrosis in Sox9
fl/fl;RosaCreER
animals, there were four experimental groups. CCl4: Sox9
fl/fl;
RosaCreER/ Olive Oil (n = 6); Sox9fl/fl;RosaCreER+/ Olive Oil
(n = 6), Sox9fl/fl;RosaCreER/ CCl4 (n = 5), and Sox9
fl/fl;RosaC-
reER+/ CCl4 (n = 8). BDL: Sox9
fl/fl;RosaCreER/ Control (n = 5);
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Sox9fl/fl;RosaCreER+/ Control (n = 5), Sox9fl/fl;RosaCreER/ BDL
(n = 7), and Sox9fl/fl;RosaCreER+/ BDL (n = 5). To determine the
effects of deleting Sox9 in both cholangiocytes and hepatocytes, CCl4
or BDL were used to induce liver fibrosis in Sox9fl/fl;AlbCre/ and
Sox9fl/fl;AlbCre+/ mice. For both models of fibrosis, this gave four
experimental groups. CCl4: Sox9
fl/fl;AlbCre/ olive oil (n = 5);
Sox9fl/fl;AlbCre+/ olive oil (n = 5), Sox9fl/fl;AlbCre/ CCl4 (n = 5)
and Sox9fl/fl;AlbCre+/ CCl4 (n = 5). BDL: Sox9
fl/fl;AlbCre/ sham
(n = 6); Sox9fl/fl;AlbCre+/ sham (n = 5), Sox9fl/fl;AlbCre/ BDL
(n = 5) and Sox9fl/fl;AlbCre+/ BDL (n = 8). A minimum of 5 mice
were used per group. Recombination status and genotype were
confirmed by PCR of DNA extracted from liver tissue.
To interrogate YAP signaling during fibrosis, in vivo verteporfin
(VP) (Sigma, UK) was injected by i.p. (Martin et al, 2016). Wild-
type C57BL/6J mice (Charles River, UK) were given i.p. CCl4 or
olive oil vehicle control as described above [and described previ-
ously (Martin et al, 2016)] for a period of 6 weeks; or bile duct
ligated. 10 ll/g body weight of 10 mg/ml VP in 10% DMSO in PBS
was injected i.p. three times weekly during the last 3 weeks of CCl4
treatment (on alternate days to CCl4 or olive oil), or every 48 h
starting on day 7 after BDL, to give a dose of 100 mg/kg body
weight. Control mice were injected with 10 ll/g body weight of
10% DMSO in PBS. This gave four treatment groups for each model
of liver fibrosis. CCl4: olive oil with DMSO (n = 5); olive oil with VP
(n = 3), CCl4 with DMSO (n = 3); and CCl4 with VP (n = 4). BDL:
sham with DMSO (n = 8), sham with VP (n = 4), BDL with DMSO
(n = 7), BDL with VP (n = 5). Levels of fibrosis and liver function
serum tests have been previously described for these animals
(Martin et al, 2016).
Liver tissue from all in vivo experiments was fixed in 4% PFA
and processed for histology as previously reported (Martin et al,
2016).
Primary cell extraction and culture
Primary rat and mouse (Male Sprague Dawley, Charles River, UK)
hepatic stellate cells (rHSCs/mHSCs, respectively) or mouse
in vivo activated HSCs were isolated and cultured as previously
described (Hanley et al, 2008; Pritchett et al, 2012; Martin et al,
2016). To interrogate YAP1 signaling, verteporfin (VP) (Sigma,
UK) was used to disrupt YAP1:TEAD complexes (Liu-Chittenden
et al, 2012). HSCs were cultured for 8 days, treated with 10 lM VP
or vehicle control for 24 h and then harvested for protein or qPCR
analysis. To model changes in mechanical stiffness, HSCs were
seeded on gels of varying stiffness (4 or 12 kPa, Cell Guidance
Systems, UK). HSCs were then harvested for protein or qPCR anal-
ysis, or fixed with 4% paraformaldehyde (Pritchett et al, 2014) for
immunofluorescence.
Protein expression
Protein expression was analyzed as previously described (Martin
et al, 2016). Antibodies used were raised against SOX9 (Millipore
AB5535 1:5,000) and anti-rabbit HRP-conjugated secondary anti-
body (GE Healthcare NA934V 1:10,000). Quantity One software
(Bio-Rad) was used for image acquisition and data analysis. HRP-
conjugated anti-b-actin antibody (Sigma A3854 1:30,000) was used
as a loading control.
Immunohistochemistry and immunocytochemistry
Tissue samples were fixed in 4% paraformaldehyde and processed
either for paraffin embedding and sectioning. Livers were embedded
in identical orientation to allow direct comparison of tissue. For
paraffin sections, tissue was dehydrated and embedded in paraffin.
Cells cultured on chamber slides were fixed in 4% paraformalde-
hyde and stored at 4°C in PBS. For diaminobenzidine (DAB) label-
ing, only tissue sections were incubated in 3% (v/v) H2O2 (Sigma,
UK) to quench endogenous peroxidase activity. Antigen retrieval
was carried out by boiling in 10 mM sodium citrate (pH 6) for
10 min, except for EpCAM IHC, for which antigen retrieval was
performed using pepsin reagent (Sigma, UK) at 37°C for 10 min.
Antigen retrieval was not performed on cells grown on hydrogels.
Tissue sections or cells were incubated in primary antibody in 0.1%
Triton X-100 in PBS containing 3% serum (serum was from the
same species the secondary antibody was raised in), overnight at
4°C. Antibodies used were anti-CK19 (Developmental Studies Hybri-
doma Bank 1:300), anti-CK7-FITC (Abcam AB118958 1:50), anti-
EpCAM (Leica Novocastra NCL-ESA 1:200), anti-F4/80 (Abcam
AB6640 1:500), anti-HNF4a (R&D Systems PP-H1415-00 1:100),
anti-SOX9 (Millipore AB5535 1:2,000), anti-TAZ (Cell Signaling
#4883 1:1,000), anti-TEAD (Cell Signaling #12292 1:1,000), anti-
YAP1 (Santa Cruz Sc-1011199 1:200), anti-a1AT (Bethyl Labs A80-
122A 1:1,000), anti-a-SMA (ICC: Leica Novocastra SMA-R-7-CE
1:100; IHC: DAKO M0851 1:100), and anti-COL1 (IHC: Southern
Biotech 1310-01 1:100). For a-SMA IHC on mouse tissue sections,
Mouse on Mouse basic detection kit (Vector Laboratories) and
Vectastain Elite Avidin Biotin Complex (ABC) system (Vector Labo-
ratories) were used. For bright-field aSMA/SOX9 dual, the Mouse
on Mouse Impress HRP polymer kit (MP-2400) and Impress AP anti-
rabbit (alkaline phosphatase) Polymer Detection kit (MP-5401)/
Impact Vector Red AP substrate (SK-5105; all from Vector Laborato-
ries) were used, respectively. After DAB (or Red AP) labeling tissue
was counterstained with Toluidine Blue. For immunofluorescence,
secondary antibodies used were 488 or 594 Alexa Fluors (Molecular
Probes, Invitrogen) raised against the appropriate species (1:1,000).
In situ mRNA hybridization
In situ detection of Sox9 and aSma RNA transcripts was carried out
on paraffin-embedded tissue sections using the RNAScope assay
(Advanced Cell Diagnostics). Sections were pretreated using an
extended protease treatment and hybridized under conditions as
described (RNAScope Sample Preparation and Pretreatment Guide)
using automated RNAScope probes for Sox9, aSma, and standard
negative Dapb (a bacterial gene) and positive Ppib control probes.
Detection was by RNAScope LS 2.5 Duplex red/brown Assay for the
Leica Bond RX autostainer (Catalog no. 322440) and Bond Polymer
Refine Red (DS9390) and Brown DAB (DS9800). Slides were coun-
terstained with hematoxylin.
Histology and analysis
Slides for morphological analysis were stained with hematoxylin
and eosin (H & E) as previously described (Piper et al, 2004). Fast
green picrosirius red (PSR) was used to stain liver sections for colla-
gen (Pritchett et al, 2014; Martin et al, 2016). The extent of scarring
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was determined by morphometric analysis of PSR and myofibroblast
accumulation by surface area covered by a-SMA staining. The 3D
Histech Panoramic 250 Flash II slide scanner was used to acquire
images of all three liver lobes on each slide. At 10× magnification,
10 images were selected from each slide at random and analyzed
with Adobe Photoshop. Stained pixels were selected using the
Colour Range tool and expressed as a fraction of the total number of
pixels. Analysis was performed blind following randomization of
slides and the acquired images.
FACS
Mononuclear blood cells (MNCs) were prepared from whole livers
of ROSACreER/ and ROSACreER+/ mice following 4 weeks’ CCl4
treatment as described above. Animals were perfused with HBSS
(0.5 mM EDTA) via the left ventricle of the heart 72 h after the final
CCl4 injection. Liver tissue was incubated with 5 ml/g digestion
buffer (0.8 U/ml Liberase-TM (Roche), 160 U/ml DNase I Type IV
(Sigma) in HBSS) for 30 min at 37°C. After homogenization using a
100-lm cell strainer and subsequent wash steps, MNCs were puri-
fied by centrifugation in a 33% Percoll density gradient. Red blood
cells were lysed using RBC Lysis buffer (Sigma). Following FCR
block, cells were stained for 30 min on ice with antibodies of interest
at the appropriate dilutions as determined by titration: B220-BV785
(1:100 Biolegend), CD11b-BV711 (1:450 Biolegend), CD11c-BV605
(1:200 Biolegend), CD45-AF700 (1:400 eBioscience), CD64-PE (1:100
Biolegend), F4/80-APC (1:300 eBioscience), Ly-6C-PE/Cy7 (1:500
Biolegend), Ly-6G-PerCP/eF710 (1:400 eBioscience), MerTK-Biotin
(1:100 R&D Systems), MHCII-eF450 (1:500 eBioscience), Siglec-F-
PE/CF594 (1:400 BD Biosciences), Streptavidin-PE/Cy5 (Biolegend).
Cells were washed in PBS and analyzed (BD FACS LSR Fortessa and
FlowJo software). Compensation was performed using UltraComp
eBeads (eBioscience). Cells passed through the cytometer were gated
by granularity and size to select single cells. Live/Dead Blue (Invitro-
gen) was used to select live cells. CD45+ cells were gated as shown
in Appendix Fig S7 to eliminate eosinophils, neutrophils, and B cells.
CD64+ Ly6C+ monocytes and macrophages were selected from the
Cd45+ Cd11b+ myeloid population for further analysis.
Human embryonic and fetal tissue
Human embryonic and fetal tissue was collected, used, and stored
with ethical approval from the North West Research Ethics Commit-
tee, following codes of practice given by the Human Tissue Author-
ity under the legislation of the UK Human Tissue Act 2008. Tissue
collection and handling was as previously described (Piper et al,
2004; Hanley et al, 2008; Jennings et al, 2013). Briefly, following
medical or surgical terminations of pregnancy, human embryos and
fetal tissues were collected and fixed in 4% paraformaldehyde and
embedded in paraffin wax for sectioning at 5-lm intervals.
Human liver biopsy collection and cell counting
Paired human liver biopsies were obtained with informed consent
and ethical approval from the Trent Cohort Study of HCV antibody-
positive patients from across the former UK Trent Health Region
(Mohsen, 2001; Ryder et al, 2004). Patient selection and data collec-
tion have been described previously (Mohsen, 2001; Ryder et al,
2004; Williams et al, 2009). Patients who received intervening ther-
apy or were infected with human immunodeficiency virus (HIV)
were excluded (Ryder et al, 2004). Liver biopsies were assessed
blindly by one of three histopathologists (Ryder et al, 2004). Biopsy
specimens > 1.5 cm long with ≥ 5 portal tracts that stained for
SOX9 by IHC were digitized using a Nanozoomer 2.0-HT slide scan-
ner and viewed with the accompanying imager (Hamamatsu,
Japan). In stained biopsy sections, five portal tract regions were
selected per slide at 200× magnification leading to the analysis of
0.28 mm2 per portal tract, within which all SOX9-positive cells were
counted and categorized by location within or outside bile ducts to
provide a mean  standard error (“SOX9 index”). The SOX9 index
was determined with no prior knowledge of disease stage, whether
initial or follow-up biopsy or whether fibrosis had progressed.
Statistics
For in vivo experiments, two-way ANOVA followed by Bonferroni
post hoc analysis was used to determine statistical significance. For
FACS experiments, significance was calculated using unpaired
t-tests with Welch’s correction. Unless otherwise stated, for all other
experiments statistical significance was determined by two-tailed
Student’s t-test. All experiments were carried out three times or
more (n = 3) as indicated.
For analysis of SOX9 in human liver biopsies, statistical analy-
sis (SPSS version 19) used either a paired two-tailed Student’s
t-test (paired data) or a chi-squared (v2) test (categorical data). In
groups with 3 or more nominal variables, means were compared
by one-way analysis of variance (ANOVA) with Tukey’s honest
The paper explained
Problem
Liver fibrosis is a major, increasing cause of death characterized by
extracellular matrix (ECM) secretion from myofibroblasts that causes
scarring and, ultimately, organ failure requiring transplant. Although
potentially reversible, predicting progression is limited and there are
currently no approved antifibrotic therapies to treat the disease. To
address, this requires in vivo knowledge of the core molecular mecha-
nisms that regulate fibrosis.
Results
SOX9 is a key transcription factor regulating expression of multiple
ECM components during normal development and in studies model-
ing isolated liver myofibroblast function in vitro. Here, we show that
prevalence of SOX9 in biopsies from patients with chronic liver disease
correlates with fibrosis severity and accurately predicts disease
progression toward cirrhosis. Inactivation of Sox9 in mice protects
against both parenchymal and biliary fibrosis, improves liver function,
and ameliorates chronic inflammation. Using multiple transgenic
models to inactivate SOX9, results support hepatic myofibroblasts as
the causative cell type-mediating fibrosis.
Impact
This study addresses an area of enormous unmet clinical need. SOX9
outperformed all other current measures predicting outcome in liver
fibrosis and would allow novel patient stratification for care and
treatment. Our data support a critical role for SOX9 in liver
myofibroblasts to promote liver fibrosis and open up the potential for
SOX9 and its dependent pathways as biomarkers or antifibrotic
targets for improving liver scarring.
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significance test (HSD) post hoc correction. Ordinal logistical regres-
sion analysis was used to evaluate the relationship between SOX9
cell count and the progression of liver fibrosis categorized by Ishak
stage with McFadden R2 indicating the degree of correlation. Area
under the receiver operator curve (AUROC) was used to quantify
the potential of the SOX9 count to predict progression of liver
fibrosis between initial and follow-up biopsy. Logistic regression
(STATA version 10) examined the impact of a number of factors
on the likelihood of showing disease progression. Results were
reported as odds ratios (OR) with 95% confidence intervals (CI).
Expanded View for this article is available online.
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